Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript – Image for illustrative purposes only (Image credits: Pexels)
Patients living with central nervous system disorders often face long waits for effective therapies, and recent supply disruptions at Supernus Pharmaceuticals have only heightened those challenges. The company’s leadership used a prominent industry forum to outline how those hurdles are now easing, with early signs of renewed momentum in patient access. The update came during a fireside chat at the Bank of America 2026 Global Healthcare Conference, where executives emphasized both operational progress and the resilience of underlying demand.
Supply Constraints Begin to Lift
Supernus has spent recent months addressing production limitations that restricted availability of its ONAPGO therapy. March 2026 marked the first complete month in which the company resumed initiating new patients at a normal pace. Early indicators from that period showed prescriptions, prescriber activity, and overall brand engagement returning to prior levels, with some measures even surpassing pre-disruption benchmarks. The focus now shifts to clearing the accumulated backlog of patient forms. Company leaders described a deliberate effort to move these cases through review and fulfillment processes as swiftly as possible, ensuring shipments reach those who have been waiting.
Demand Holds Steady Despite Earlier Limits
One of the more striking elements of the update was the continued strength of physician interest even while supply remained constrained. Rather than pausing referrals, doctors kept submitting patient forms and maintaining waitlists, confident that the therapy would become available again. Data shared at the conference illustrated this trend clearly. Approximately 500 new forms arrived during the fourth quarter of 2025, at the height of the supply issues. Another 400 forms were submitted in the first quarter of 2026. These figures underscore that awareness and need for the treatment remained high throughout the period. Jack A. Khattar, the company’s president and chief executive officer, captured the situation in remarks at the event: “Let me remind that we’re going back to normal, so to speak, initiating new patients back to the right track in launching the product. And March was the first month, of course, full month since we made that change and reinitiation of patients. And we’re very pleased with all the metrics in March from prescriptions, number of prescribers, the activity behind the brand across several measures. So in certain cases, actually even higher than before the supply constraints.”
Next Steps for Broader Patient Access
With supply lines stabilizing, attention turns to accelerating the conversion of queued forms into active therapy starts. The company has signaled that processing speed will remain a priority in the coming weeks, aiming to reduce wait times for those already in the system. This phase carries direct implications for individuals managing movement disorders who rely on consistent treatment options. Faster throughput could translate into earlier relief for patients who have navigated the recent constraints.
Broader Context for CNS Therapies
The presentation also placed the ONAPGO recovery within the larger landscape of central nervous system care. Supernus continues to position itself as a specialist in this therapeutic area, where reliable product availability can meaningfully affect daily function and quality of life for those affected. Observers at the conference noted that the combination of recovering supply and sustained demand positions the company to regain ground lost during the earlier limitations. The coming months will reveal how quickly the backlog clears and whether the positive March trends hold. For patients and prescribers alike, the message from Las Vegas offered measured reassurance that the pathway to treatment is once again opening.
